Due to its long half-life (78 h) and decay properties (77% electron capture, 23% β + , E max = 897 keV, E av = 397 keV, Eγ = 909 keV, Iγ = 100%) 89 Zr is an appealing radionuclide for immunoPET imaging with whole 
Introduction
Antibodies have great utility in the clinic, and can be used without modification as therapeutics or as conjugates in radiotherapy or drug delivery. Currently, the FDA has approved 30 monoclonal antibodies for clinical use, with 12 of these approved for oncological treatments, and hundreds more are in clinical trials. 1 The ability to image antibody biodistribution and tissue localisation in vivo is useful in patient prognosis and dosimetry and in guiding selection of therapeutic regimes and monitoring disease response to antibody-based therapies, and in stratifying patients for clinical trials. Imaging † Electronic supplementary information (ESI) available: 1 H and 13 C NMR data, reverse phase HPLC and size exclusion HPLC chromatograms, phosphoimages of ITLC plates, ex vivo biodistribution data. See DOI: 10.1039/c4dt02978j antibody distribution in vivo has been mainly achieved with the use of γ-emitting radionuclides, especially 111 In 2,3 and 99m Tc. 4, 5 In recent years there has been increased interest in using positron emission tomography (PET) to study antibody biodistribution. 6 The large molecular weight (∼150 kDa) of whole antibodies results in slow accumulation in target tissue, while the lack of domains that mediate clearance and excretion leads to slow blood clearance. Consequently, extended time periods (0.5-7 days) are required for the antibody to clear from non-target tissue and localise at cell receptors in target tissue. The β + -emitting isotope 89 Zr allows these requirements to be met, possessing suitable decay properties (77% electron capture, 23% β + , E max = 897 keV, E av = 397 keV, Eγ = 909 keV, Iγ = 100%) and a half-life of 78.5 h. [6] [7] [8] [9] Zr 4+ can accommodate up to eight donors in its coordination sphere and the high charge of Zr 4+ induces a preference for "hard" Lewis acid donor atoms. 8 The 89 Zr have been successfully employed in imaging tumours or tumour markers in murine models 15, [17] [18] [19] [20] [21] [22] [23] and have demonstrated the ability to image known and unknown tumour lesions in patients in clinical trials. [24] [25] [26] A very recent study has described an octadentate chelator containing four linear hydroxypyridinone groups (each a 1-hydroxy-pyridin-2-one) that is able to coordinate 89 Zr 4+ quantitatively. 27 The resulting complex demonstrates comparable stability to that of [ 89 Zr(DFO)] + , however to the best of our knowledge, a bifunctional derivative of this complex has not been reported, and the stability of the complex over extended periods of time in vivo (>24 h) has not been assessed. Another recent report details the synthesis and 89 Zr 4+ labelling of a series of octadentate ligands each containing four hydroxamate ligands. 28 Linear and macrocyclic derivatives differing in distance between adjacent hydroxamate groups were prepared, and the The bifunctional chelator H 3 YM103, which contains a maleimide group, was originally developed to allow facile site-specific modification of proteins through engineered cysteine residues. The tris(hydroxypyridinone) ligands are efficient at extremely low concentrations of chelator, and the resulting complexes and bioconjugates are stable under in vivo biological conditions. With its six oxygen donors, we speculated that by analogy to H 3 (Fig. 6D ). Both sets of reactions were also duplicated in phosphate buffer ( pH 7.4, 0.1 M) for solutions containing competing chelator at 1 mM and 10 mM concentrations, resulting in identical outcomes.
To verify that these reaction products were in fact equilibrium products (as opposed to kinetic products), 1 equivalent of H 3 CP256 (10 μL, 1 mM H 3 CP256) was added to 10 The ratios of products were the same as those previously observed for the same ratio of chelators (Fig. S4 , ESI †). Thus the order in which the solutions are labelled in these experiments is inconsequential as the reactions are under thermodynamic control.
Lastly, it is conceivable that rapid re-equilibration takes place on the C18 reverse phase HPLC column under the acidic mobile phase conditions (0.1% trifluoroacetic acid, pH 1-2 Error bars correspond to one standard deviation.
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This journal is © The Royal Society of Chemistry 2015 Following TCEP reduction and conjugation and under the conditions utilised for ESI-MS analysis the heavy and light chains of the antibody dissociated in the gas phase, giving rise to separate signals. In contrast, the ESI mass spectrum of non-TCEP-treated unmodified trastuzumab antibody revealed that unmodified/unreduced trastuzumab did not dissociate into heavy and light chain fragments. To facilitate analysis and enable comparison between conjugated and unconjugated trastuzumab antibody fragments, a sample of trastuzumab was treated with TCEP and separated using a NAP5 Sephadex cation exchange column. This sample was immediately subjected to ESI-MS analysis. Subsequent deconvolution of the spectrum revealed the molecular weight of reduced trastuzumab fragments that separated in the gas phase -in this case, the unconjugated light, heavy and heavy-light chains. The molecular weight of each observed fragment of reduced trastuzumab and the H 3 DFO and H 3 YM103 trastuzumab immunoconjugates is listed in Table 2 .
ESI-MS analysis of trastuzumab immunoconjugates, followed by deconvolution of the subsequent spectrum, revealed that four to eight H 3 DFO groups were attached to each trastuzumab antibody. In the case of a species conjugated to eight H 3 DFO groups, three H 3 DFO chelators were attached to each heavy chain and one attached to each light chain. There were no signals corresponding to unconjugated light chain, or a heavy chain conjugated to less than three H 3 DFO groups. In the case of a species conjugated to four H 3 DFO groups, the corresponding mass spectral signals indicated that two H 3 DFO groups were attached to each associated heavy-light chain fragment. No unconjugated fragments were observed in this spectrum. For H 3 YM103-trastuzumab, the mass spectrum indicated that a mixture of species was present, varying in the number of attached H 3 YM103 groups. From the relative intensities of signals in the ESI mass spectrum, it appeared that only a small fraction of light chain fragments were conjugated to a single H 3 YM103 and the strongest light chain signal corresponded to unconjugated light chain. Signals observed for the heavy chain corresponded to heavy chain conjugated to zero to three H 3 YM103 groups. Signals were also observed for associated heavy-light chain fragments, conjugated to zero, one and two H 3 YM103 groups, all of comparable total ion count intensity.
It is also noteworthy that each heavy chain signal and each heavy-light chain signal in the spectra of both immunoconjugates and reduced trastuzumab was accompanied by an additional signal with a difference of 162-164 Da. This signal corresponds to one additional hexose unit suggesting the presence of differently glycosylated forms of the heavy chain of trastuzumab in the gas phase.
Size exclusion HPLC measurements were used to determine the radiochemical yield of 89 Zr-labelled immunoconjugates, and as the radiochemical yield and purity were >98% at the specific activities listed below, no further purification was undertaken. (Fig. S6 †) . After incubation in serum for 2 days, both 89 Zr-DFO-trastuzumab and 89 Zr-YM103-trastuzumab were intact, and at 7 days, >95% of 89 Zr remained associated with the mAb fraction (Fig. S6 †) .
Over this time, some aggregation of 89 Zr-YM103-trastuzumab occurred in the serum solution, as evidenced by the appearance of shoulder peaks at lower retention times. In the course of these studies, it was also observed that neither native (unmodified) trastuzumab nor reduced trastuzumab (unconjugated to chelators) coordinated 89 Zr 4+ .
In By 15 min post-injection (PI), some 89 Zr activity had accumulated at bones and joints (see knee joint in Fig. 8 ) and this continued to increase over time. Significant activity was associated with the blood pool during the first hour PI. By 4 h PI, 89 Zr had significantly accumulated in bones and joints, although some activity was still observed in the blood pool with the animal retaining approximately 98% of the original injected dose (decay corrected, calculated from PET coincidence rates).
In marked contrast, [ 89 Zr(CP256)] + cleared from the blood pool rapidly via a renal pathway ( Fig. 8 and S7 †) . For the three animals used in this study, at 15 min PI, 15-35% of injected dose was associated with the bladder, and at 60 min PI, the majority of the injected activity was associated with the bladder (55-75% of the injected dose, Fig. 8 and S7 †), although the kidneys (1.5-10% injected dose) were also visible in the whole body scan. This is comparable to what has previously been reported for [ 89 Zr(DFO)] + . 15 After 4 h PI, the fraction of the original injected dose remaining associated with each animal was 7% for mouse 1, 8% for mouse 2 and 4% for mouse 3, enabling the kidneys and bladder to be visualised in all three cases (e.g. Fig. 8 ). , 98% of the injected dose remains 4 h PI, and is associated predominantly with the skeleton. Different scaling has been used for the top three images on the left, because non-bladder activity was so low that the kidneys could not be visualised without brightness/contrast enhancement.
This Additionally and 89 Zr-YM103-trastuzumab (26.1 ± 2.3%ID g −1 ). For 89 Zr-DFO-trastuzumab, the relative bone-associated activity had not altered (7.8 ± 0.7%ID g −1 ), whereas for 89 Zr-YM103-trastuzumab, relative bone-associated activity almost doubled (15.1 ± 1.6%ID g −1 ) compared to that observed at the 6 h PI time point (Fig. 10) . Over the course of a week, relative boneassociated activity for animals injected with 89 Zr-DFO-trastuzumab did not increase (5.1 ± 0.2%ID g −1 at 3 days PI, and 6.5 ± 0.4%ID g −1 at 7 days PI) but bone-associated activity for animals injected with 89 Zr-YM103-trastuzumab increased to 29.0 ± 3.3%ID g −1 at 3 days PI, and did not change substantially thereafter (25.9 ± 0.6%ID g −1 at 7 days PI). For 89 Zr-DFOtrastuzumab, blood associated activity decreased to 27.2 ± 1.0%ID g −1 at 3 days PI and slightly further to 24.4 ± 1.3%ID g −1 at 7 days PI. For 89 Zr-YM103-trastuzumab, blood associated activity decreased to 24.1 ± 1.3%ID g −1 at 3 days PI and then significantly further to 12.9 ± 0.2%ID g −1 at 7 days PI. At the conclusion of the experiment (7 days), the ratio of blood/bone activity (as a ratio of %ID g −1 values) was 3.7 for animals injected with 89 Zr-DFO-trastuzumab, whereas for animals injected with 89 Zr-YM103-trastuzumab, the ratio was 0.5. For both immunoconjugates, the high %ID g −1 in lung, and its clearance, parallels that in the blood pool suggesting that the lung radioactivity is largely confined to blood and in this respect is typical of radiolabelled antibodies showing delayed clearance from blood. PET scans acquired at 0.5 h, 6 h, 1 day, 3 days and 7 days PI were consistent with biodistribution data for both 89 Zr-labelled immunoconjugates (Fig. 11) . PET images of animals imaged with 89 Zr-labelled immunoconjugates exhibited predominantly blood pool associated activity at the 6 h PI time point. After this time point, the blood pool was still clearly visible out to 7 days PI for the animal administered 89 Zr-DFO-trastuzumab, although some bone activity was observed -for example, the knee joints were visible from 1 day PI onwards. For the animal administered 89 Zr-YM103-trastuzumab, the blood pool was PI, bone uptake is higher than blood retention for animals administered 89 Zr-YM103-trastuzumab, whereas for animals administered 89 Zr-DFOtrastuzumab, activity in blood is higher than that associated with bone. visible by PET at 1 day PI, but from 3 days PI, activity was predominantly associated with the skeleton. Indeed, from 1 day PI, the knee joints of this animal were as prominent in the scan as the blood pool, and at 3 days PI, and even more so at 7 days PI, the vertebrae, skull and major joints of the animal were clearly distinguishable. The striking difference observed in the comparison of the ratios of blood : bone activity concentration (from ex vivo biodistribution data of the two 89 Zr-labelled immunoconjugates at 7 days PI) was clearly discernable when qualitatively comparing the PET images for the same time point. Overall, the biodistribution and PET scanning data point to significantly lower in vivo stability of 89 39 These species result in multiple sets of signals in the 13 C NMR spectrum in the 13 CvO region, and it has been proposed that the rearrangement process would not necessitate a transition state involving dissociation of the ligand from the metal. In the case of Zr 4+ , which likely accommodates eight ligands, 15 there was no description of this type of geometric isomerism in the DFT calculations. We only detect a single set of peaks in the 13 CvO region of the 13 C NMR spectrum. Indeed, if cis-trans isomers (arising from a change in coordination geometry of hydroxamate O ligands) interconvert in solution, the process cannot be detected by 13 C NMR under the experimental conditions employed for this study, although mechanisms could be conceived by which such isomerism occurs, and such isomerism has been observed for an octadentate Zr 4+ complex of four bidentate N-methyl acetohydroxamate ligands. 16 Finally, on the basis of NMR data, primary amine coordination to Zr 4+ cannot be ruled out, although in light of previously reported DFT calculations 15 and the small differences in 13 Under the same reaction conditions, the conjugation of H 3 YM103 to trastuzumab was less efficient than the conjugation of a maleimidopropionate-H 3 DFO derivative to trastuzumab. This reduced reactivity for H 3 YM103 is possibly a consequence of the increased steric bulk of the hydroxypyridinone rings compared to the linear H 3 DFO chain, resulting in a decrease in the number of chelators that can be accommodated at reduced cysteine side chains in close proximity to one another, or consequently a decrease in the rate of reaction at these cysteines.
The Geometric rigidity and kinetic inertness of radiolabelled complexes is demonstrably important for in vivo stability for other radiometallic imaging agents, 7, 46, 47 4 ], 16 it is likely that the incorporation of four rather than three bidentate chelators into a suitable topology will be required to improve on the Zr-chelating properties of DFO. Indeed, recently reported stability constant data indicates a preference for 1 : 4 complexes for the Me-AHA complex. 16 We, like others, 16, 27 
Experimental

Materials and instrumentation
Chemicals and reagents were obtained from Sigma-Aldrich (Dorset, UK) unless otherwise specified. The highest available purity (lowest metal ion-containing) chemicals were used. Sterile water for injection, used to prepare buffers, was obtained from Baxter Healthcare (Newbury, UK). G-25 Illustra NAP-5 size exclusion columns were purchased from Fisher Scientific Ltd (Leicestershire, UK) and washed with 0.1 M ammonium acetate solution, pH 6. Trastuzumab (MabThera, Roche) was obtained as a 10 mg mL −1 solution from the Pharmacy Department at Guy's and St. Thomas' NHS Trust, London. Fresh female O + type human serum was obtained from a healthy volunteer. High-performance liquid chromatography (HPLC) analysis was carried out using an Agilent 1200 LC system with in-line UV and gamma detection (Flow-Count, LabLogic). NMR spectra were acquired on a Bruker Avance 400 spectrometer (Bruker UK Limited, Coventry, UK) equipped with a 5 mm QNP probe at 400.13 MHz for 1 H NMR spectra (using a zg30 pulse program) and 100.6 MHz for 13 C NMR spectra (using a zgpg30 pulse program), or in the case of low temperature variable temperature experiments, a Bruker Avance 500 spectrometer with a triple resonance cryoprobe with z-gradients at 500 MHz for 1 H NMR spectra (using a zg30 pulse program), or in the case of high temperature variable temperature experiments in deuterium oxide, a Bruker Avance 400 spectrometer with a PH BBO probe at 400.13 MHz for 1 H NMR spectra (using a zg30 pulse program). Spectra were referenced to residual solvent signals, or in the case of deuterium oxide, an acetone reference. Mass spectra were recorded in the positive ion mode on an Agilent 6520 Q-TOF LC/MS mass spectrometer coupled to an Agilent 1200 LC system (Agilent, Palo Alto, CA). Data were acquired and reference mass-corrected via a dual-spray electrospray ionisation source, using the factory-defined calibration procedure. Analytical reverse phase LCMS and radio-LCMS traces were acquired using an Eclipse XDB-C18 column (4.6 × 150 mm, 5 μm) with a 0.5 mL min −1 flow rate and UV spectroscopic detection at either 214 nm, 256 nm or 270 nm. The LCMS was coupled to a LabLogic Flow-Count detector with a sodium iodide probe (B-FC-3200) to give a triple-readout chromatogram (UV-vis, radioactivity and total ion count). Instant thin layer chromatography strips (ITLC-SG) were obtained from Varian Medical Systems UK, Ltd. (Crawley, UK), and ITLC strips were visualised using a Perkin Elmer Storage Phosphor System (Cyclone). Analytical reverse phase HPLC and radio-HPLC traces were acquired using an Agilent 1200 LC system and an Agilent Zorbax Eclipse XDB-C18 column (4.6 × 150 mm, 5 μm) with a 1 mL min −1 flow rate and UV spectroscopic detection at either 214 nm, 256 nm or 270 nm. Analytical size exclusion radio-HPLC traces were acquired using an Agilent 1200 Series HPLC system and a Phenomenex Biosep 2000 (300 × 7.8 mm) size exclusion column with ammonium acetate (0.1 M) mobile phase and, unless otherwise specified, sodium ethylenediamine tetraacetate (2 mM). The radio-HPLC was coupled to a LabLogic Flow-Count detector with a sodium iodide probe (B-FC-3200). Aliquots (10-200 μL) of each radiolabelled sample were injected onto the column, using a flow rate of 1 mL min −1 . Samples were also prepared using deuterium oxide in place of methanol-d 4 . Spectroscopic data are included in Fig. 1-3 Zr-immunoconjugate solutions were both diluted to 1.3 mL to provide 12 injections (100 μL each) for biodistribution studies.
Serum stability studies: 89 Zr-DFO-trastuzumab and 89 Zr-YM103-trastuzumab were radiolabelled as described above to achieve specific activities of 14 MBq mg −1 . An aliquot of each immunoconjugate (30 μL, 0.11 mg of immunoconjugate, 1.5 MBq) was incubated with fresh serum (200 μL O + fresh human serum from a healthy female volunteer) for 24, 48 or 168 h, after which it was analysed using size exclusion HPLC. (1-2000 nM) in HBSS with 0.2% BSA (1 mL) were incubated with the cells on ice for 1 h in triplicate. The cells were washed 3 times by centrifuging at 1000 rpm for 3 min, aspirating the supernatant and washing with ice-cold HBSS (1 mL). After this, radioactivity associated with cell pellets was counted using a Wallac 1282 Compugamma Universal Gamma Counter. A one site total binding fit using Prism 5.04 for Windows was used to fit the curves and determine the dissociation constants. The above procedure was also used to determine the dissociation constant for 89 Zr-DFOtrastuzumab.
In vivo biodistribution and PET imaging studies weeks-old male C57Bl/6j mice (n = 3) were purchased from Harlan UK and left to acclimatise for five days before use with ad libitum access to water and diet. PET images were acquired in a nanoScan® PC in vivo pre-clinical PET/CT imager (Mediso, Hungary). For PET imaging a mouse was anesthetised by inhalation of a 3% isoflurane-oxygen mixture and placed on the scanner bed; general anaesthesia was maintained with a 1. PET scans were acquired in a nanoPET scanner at 0.5 h, 6 h, 1 day, 3 days and 7 days PI. Mice were culled by cervical dislocation at the end of the study. All studies were approved by the institutional committee and conducted in strict compliance with Home Office (UK) guidelines on animal experimentation and the corresponding personal and project licenses.
